Benitec Biopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-4.3%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$1.00next fiscal year
Monitoring Framework
Key Performance Indicators
BB-301 Phase 1b/2a Clinical Trial Enrollment and Dosing Quarterly2.0Target: Complete Cohort 2 high-dose patient dosing and follow-up
Cash and Cash Equivalents Quarterly184.8MTarget: Sufficient to fund operations through completion of the BB-301 pivotal study
Quarterly Net Loss Quarterly-11.9MTarget: Manageable cash burn rate aligned with clinical milestones
Watch Items
- FDA Engagement on BB-301 Pivotal Study DesignTrigger: Formalization of the Phase 2/3 pivotal study protocol with the FDAAction: Confirm clinical endpoints, patient size, and regulatory pathway for accelerated approval
- Interim Clinical Data Readouts for Cohort 1 and Cohort 2Trigger: Release of updated 2H-2026 clinical efficacy and safety dataAction: Evaluate swallowing function improvements (Sydney Swallow Questionnaire, radiographic metrics) and safety profiles
- Board Composition and Governance ReviewTrigger: Further changes to the Board of Directors following CFO Megan Boston's transitionAction: Monitor alignment of board expertise with clinical-stage execution and commercialization planning
Research as of 19 Jun 2026